Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose
Brief Summary: This study is a follow-up of Pfizer studies using rLP (treatment assignment known) and investigational product (treatment assignment unknown) in which the subjects will attend up to 6 study visits for collection of a 20-mL blood sample at each visit.